0.53
-0.044(-7.70%)
Currency In USD
| Previous Close | 0.57 |
| Open | 0.56 |
| Day High | 0.54 |
| Day Low | 0.47 |
| 52-Week High | 6.3 |
| 52-Week Low | 0.47 |
| Volume | 839,131 |
| Average Volume | 3.53M |
| Market Cap | 1.91M |
| PE | -0.06 |
| EPS | -8.48 |
| Moving Average 50 Days | 0.78 |
| Moving Average 200 Days | 1.66 |
| Change | -0.04 |
If you invested $1000 in ZyVersa Therapeutics, Inc. (ZVSA) since IPO date, it would be worth $0.15 as of May 10, 2025 at a share price of $0.527. Whereas If you bought $1000 worth of ZyVersa Therapeutics, Inc. (ZVSA) shares 2 years ago, it would be worth $2.96 as of May 10, 2025 at a share price of $0.527.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
GlobeNewswire Inc.
May 07, 2025 11:57 AM GMT
WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments fo
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease
GlobeNewswire Inc.
Apr 29, 2025 11:57 AM GMT
Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study.Parkinson’s Disease (PD) affects over 10 million people glob
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
GlobeNewswire Inc.
Apr 24, 2025 11:57 AM GMT
WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseas